IHC- ER, PR Test, Price, Normal Range | Sprint Diagnostics Hyderabad

This test is performed on a tissue biopsy sample. The sample is treated with specific antibodies designed to bind to the estrogen and progesterone receptors. If these receptors are present in the tissue, the antibodies will attach, and this interaction can be visualized under a microscope.

No, fasting is not required before this test.

No specific preparations are needed for this test.

Your healthcare provider might recommend the IHC- ER, PR test if they suspect a disease that can be diagnosed or managed through hormone receptor detection, such as breast cancer.

The test results are usually reported as positive or negative for each receptor examined. A positive result means the receptor was detected in the tissue sample, which can significantly influence treatment options. A negative result indicates the receptor was not detected. The interpretation of these results should be discussed with your healthcare provider.

The frequency of this test is determined by your healthcare provider based on your health situation. It's usually ordered when there's clinical suspicion of a disease that can be diagnosed or managed using hormone receptor detection.

There are no specific precautions necessary for the IHC- ER, PR test. However, it's always good to communicate any allergies or medications you're taking to your healthcare provider, as these could potentially affect the biopsy procedure.

While it's rare, the IHC- ER, PR test results could be influenced by technical errors during the biopsy or testing procedure.

A positive test result indicates the presence of one or both of the tested hormone receptors in your tissue sample. In such a case, discuss the results with the healthcare provider who ordered the test. They may refer you to a specialist, such as an oncologist, for further evaluation and treatment planning.

Yes, the IHC- ER, PR test can be used for both diagnosis and monitoring of diseases. The test offers critical information about the presence or absence of hormone receptors, which can help inform treatment strategies.

Yes, the IHC- ER, PR test can be performed on individuals of all ages, including children. The necessity and appropriateness of this test are determined based on your healthcare provider's clinical judgment.

While the IHC- ER, PR test itself poses minimal risk, the biopsy procedure used to obtain the tissue sample can carry some risks, including infection, bleeding, and an adverse reaction to anesthesia.

While uncommon, it is possible to receive false positive or negative results from the IHC- ER, PR test due to technical errors during the testing process. Always discuss your results with your healthcare provider to gain a comprehensive understanding.

The decision to conduct the IHC- ER, PR test during pregnancy depends on the potential benefits and risks, which should be discussed with your healthcare provider.

The type of tissue sample required for the IHC- ER, PR test depends on the suspected location of disease or abnormality. The sample is usually obtained through a biopsy procedure.

A positive IHC- ER, PR result means the specific hormone receptors were detected in the tissue sample. This can suggest certain diseases or conditions, but the interpretation depends on the specific receptors detected and other clinical findings.

There are no known medications that directly interfere with the IHC- ER, PR test. However, it's always important to discuss all the medications and supplements you're currently taking with your healthcare provider before the test.

The IHC- ER, PR test is a reliable tool when used in conjunction with other tests and clinical findings. However, no single test should be used as the sole basis for diagnosis. Your healthcare provider will consider these test results along with other diagnostic information.

Lifestyle factors do not directly affect the results of the IHC- ER, PR test, as it measures specific hormone receptors in a tissue sample. However, maintaining a healthy lifestyle can contribute positively to overall health and wellbeing.

The IHC- ER, PR test plays a crucial role in the diagnosis and management of hormone receptor-positive cancers. It can provide critical information about the presence or absence of estrogen and progesterone receptors, which can greatly influence treatment strategies. However, like any test, it should be interpreted in the context of a comprehensive clinical picture. Always consult with your healthcare provider for a thorough understanding of your test results and their implications on your health.